Considering role of CAFs in the progression of MM, the use of recombinant human erythropoietin as a potential therapeutic strategy can inhibit cell proliferation of MM patient-derived CAFs while increasing CAFs apoptosis (168). The gene discussed is EPO; the disease is Miyoshi myopathy.